IL115849A0 - Tangential filtration preparation of liposomal drugs and liposome product thereof - Google Patents

Tangential filtration preparation of liposomal drugs and liposome product thereof

Info

Publication number
IL115849A0
IL115849A0 IL11584995A IL11584995A IL115849A0 IL 115849 A0 IL115849 A0 IL 115849A0 IL 11584995 A IL11584995 A IL 11584995A IL 11584995 A IL11584995 A IL 11584995A IL 115849 A0 IL115849 A0 IL 115849A0
Authority
IL
Israel
Prior art keywords
tangential filtration
liposome product
liposomal drugs
filtration preparation
preparation
Prior art date
Application number
IL11584995A
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Publication of IL115849A0 publication Critical patent/IL115849A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
IL11584995A 1994-11-03 1995-11-02 Tangential filtration preparation of liposomal drugs and liposome product thereof IL115849A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33379094A 1994-11-03 1994-11-03

Publications (1)

Publication Number Publication Date
IL115849A0 true IL115849A0 (en) 1996-01-31

Family

ID=23304261

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11584995A IL115849A0 (en) 1994-11-03 1995-11-02 Tangential filtration preparation of liposomal drugs and liposome product thereof

Country Status (2)

Country Link
IL (1) IL115849A0 (en)
WO (1) WO1996014057A1 (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
JP4467789B2 (en) 1997-09-18 2010-05-26 パシラ ファーマシューティカルズ インコーポレーテッド Sustained release liposome anesthetic composition
WO1999025319A1 (en) * 1997-11-14 1999-05-27 Depotech Corporation Production of multivesicular liposomes
EP1633770B1 (en) 2003-06-13 2015-04-29 Alnylam Europe AG Double-stranded ribonucleic acid with increased effectiveness in an organism
AU2004305563C1 (en) 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CN1921893B (en) 2004-02-24 2011-11-09 综合医院公司 Catalytic radiofluorination
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
BRPI0511070A (en) 2004-06-17 2007-11-27 Infinity Pharmaceuticals Inc compounds and processes for inhibiting the interaction of bcl proteins with binding partners
WO2006124726A2 (en) 2005-05-12 2006-11-23 The General Hospital Corporation Novel biotinylated compositions
CA2659747C (en) 2006-08-03 2015-09-08 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
EP2065058A1 (en) 2007-11-28 2009-06-03 Koninklijke Philips Electronics N.V. Non-spherical contrast agents for CEST MRI based on bulk magnetic susceptibility effect
EP2067485A1 (en) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement
PL2331092T3 (en) 2008-08-21 2014-08-29 Univ Johns Hopkins Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
PT3133160T (en) 2008-10-24 2019-03-18 Sarepta Therapeutics Inc Exon skipping compositions for dmd
EP2403863B1 (en) 2009-03-02 2013-08-28 Alnylam Pharmaceuticals Inc. Nucleic acid chemical modifications
EP2305216A1 (en) 2009-09-25 2011-04-06 Koninklijke Philips Electronics N.V. Two step ultrasound protocol for drug delivery
BR112012011381B8 (en) 2009-11-13 2021-05-25 Avi Biopharma Inc Isolated antiviral antisense oligonucleotide and pharmaceutical composition comprising the same
US9068185B2 (en) 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
US9238042B2 (en) 2010-05-13 2016-01-19 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
AU2011270719B2 (en) 2010-06-24 2015-09-24 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
US8450316B2 (en) 2010-06-24 2013-05-28 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
EP2407157A1 (en) 2010-07-13 2012-01-18 Koninklijke Philips Electronics N.V. Lipid bilayer carrier for drugs or imaging agents
CN103338747A (en) 2011-01-28 2013-10-02 皇家飞利浦电子股份有限公司 Carriers for the local release of hydrophilic prodrugs
EP2535326A1 (en) 2011-06-16 2012-12-19 Koninklijke Philips Electronics N.V. Novel lipidomimetic compounds and uses thereof
MX2013015434A (en) 2011-06-22 2014-10-14 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs.
EP2732035A2 (en) 2011-07-15 2014-05-21 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
PT2788487T (en) 2011-12-08 2018-07-03 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CN104125953A (en) 2011-12-23 2014-10-29 诺华股份有限公司 Compounds for inhibiting interaction of bcl2 with binding partners
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
BR112014015442A8 (en) 2011-12-23 2017-07-04 Novartis Ag compounds and compositions for inhibiting bcl2 interaction with binding partners
MX2014007729A (en) 2011-12-23 2015-01-12 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners.
EA201492007A1 (en) 2012-05-15 2015-03-31 Новартис Аг DERIVATIVES OF BENZAMIDE FOR INHIBITION OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY
JP6080947B2 (en) 2012-05-15 2017-02-15 ノバルティス アーゲー Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2013171640A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
NZ701626A (en) 2012-05-15 2016-02-26 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
US9655977B2 (en) 2012-08-31 2017-05-23 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
CN106414739A (en) 2012-12-20 2017-02-15 萨雷普塔医疗公司 Improved exon skipping compositions for treating muscular dystrophy
LT2958907T (en) 2013-02-19 2018-04-25 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
RS58529B1 (en) 2013-03-14 2019-04-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
EP2970963B1 (en) 2013-03-14 2019-10-23 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
BR112015022998A2 (en) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc improved compositions for treating muscular dystrophy
US10017531B2 (en) 2013-06-14 2018-07-10 Invictus Oncology Pvt. Ltd. Lipid-based platinum-N-heterocyclic carbene compounds and nanoparticles
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
ES2699351T3 (en) 2014-01-17 2019-02-08 Novartis Ag Derivatives of 1-pyridazin / triazin-3-yl-piper (-azine) / idine / pyrolidine and compositions thereof to inhibit the activity of SHP2
CN113559105A (en) 2014-01-29 2021-10-29 维奥姆治疗有限公司 Treatment of resistant acne
UA120849C2 (en) 2014-03-12 2020-02-25 Ніппон Шин'Яку Ко., Лтд. Antisense nucleic acid
KR20160132496A (en) 2014-04-03 2016-11-18 인빅터스 온콜로지 피비티. 엘티디. Supramolecular combinatorial therapeutics
CA2970795A1 (en) 2014-12-18 2016-06-23 Alnylam Pharmaceuticals, Inc. Reversir compounds
ES2918385T3 (en) 2015-05-19 2022-07-15 Akamara Therapeutics Inc Process for the preparation of supramolecular compounds based on platinum
WO2016196664A1 (en) 2015-06-01 2016-12-08 Cedars-Sinai Medical Center Methods and use of compounds that bind to rela of nf-kb
JP6878316B2 (en) 2015-06-19 2021-05-26 ノバルティス アーゲー Compounds and compositions for inhibiting the activity of SHP2
ES2741746T3 (en) 2015-06-19 2020-02-12 Novartis Ag Compounds and compositions to inhibit SHP2 activity
CN107922388B (en) 2015-06-19 2020-12-29 诺华股份有限公司 Compounds and compositions for inhibiting SHP2 activity
TW201722965A (en) 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 Compounds for use in antibacterial applications
EP3355892A4 (en) 2015-09-30 2019-05-22 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
WO2017064657A1 (en) 2015-10-16 2017-04-20 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
EP3370712A4 (en) 2015-11-06 2019-10-09 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
MA45616A (en) 2016-04-29 2019-03-06 Sarepta Therapeutics Inc TARGET OLIGONUCLEOTIDE ANALOGUES LMNA HUMAN
ES2849560T3 (en) 2016-05-04 2021-08-19 Genoscience Pharma Sas Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
CA3023216A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3478697A1 (en) 2016-06-30 2019-05-08 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
ES2927079T3 (en) 2016-12-19 2022-11-02 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
AU2017382773A1 (en) 2016-12-19 2019-08-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
PT3554554T (en) 2016-12-19 2022-11-08 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
AU2018256435A1 (en) 2017-04-20 2019-11-07 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
EA201991450A1 (en) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
EP3687547A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
EP3687577A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
EP3687519A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
TW202020153A (en) 2018-07-27 2020-06-01 美商薩羅塔治療公司 Exon skipping oligomers for muscular dystrophy
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
JP2022511055A (en) 2018-12-13 2022-01-28 サレプタ セラピューティクス， インコーポレイテッド Exon skipping oligomer conjugate for muscular dystrophy
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
WO2020168283A1 (en) 2019-02-14 2020-08-20 Akamara Therapeutics, Inc. Compounds and methods for managing cancer through immune system
SG11202108757XA (en) 2019-03-28 2021-10-28 Sarepta Therapeutics Inc Methods for treating muscular dystrophy with casimersen
EP3955966A1 (en) 2019-04-18 2022-02-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
JP2022536495A (en) 2019-06-19 2022-08-17 サレプタ セラピューティクス， インコーポレイテッド How to treat muscular dystrophy
IL294271A (en) 2019-12-26 2022-08-01 Nippon Shinyaku Co Ltd Antisense nucleic acid that induces skipping of exon 50
CN115210376A (en) 2020-02-28 2022-10-18 日本新药株式会社 Antisense nucleic acids inducing skipping of exon 51
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
AU2023235302A1 (en) 2022-03-17 2024-10-24 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2024073570A1 (en) 2022-09-28 2024-04-04 Altos Labs, Inc. Expression of regeneration factors in aged/senescent cells
WO2024155957A1 (en) 2023-01-19 2024-07-25 Altos Labs, Inc. Use of regeneration factors in organ transplantation
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2877160B2 (en) * 1987-07-29 1999-03-31 ザ リポソーム カンパニー，インコーポレイテッド Separation method by particle size
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
DE69224622T2 (en) * 1991-10-04 1998-11-05 Dade Behring, Inc., Deerfield, Ill. PRODUCTION OF PROTHROMBINE TIME REAGENTS FROM RECOMBINANT HUMAN TISSUE FACTOR AND SYTHETIC PHOSPHOLIPIDS

Also Published As

Publication number Publication date
WO1996014057A1 (en) 1996-05-17

Similar Documents

Publication Publication Date Title
IL115849A0 (en) Tangential filtration preparation of liposomal drugs and liposome product thereof
GB2313310B (en) Local delivery and monitoring of drugs
AU4990397A (en) Compound-loaded liposomes and methods for their preparation
PL322624A1 (en) Skin care composition containing retinoides and liposomes
AU2002301268A1 (en) Production of multivesicular liposomes
PL313386A1 (en) Novel pearls ensuring controllable drug release and pharmaceutic preparation containing them
EP0863748A4 (en) Liposomal compositions and methods of using them
SK63795A3 (en) Metallocene catalytic synthesis method of their preparation and use
EP0750910A4 (en) Liposome preparation
IL118469A0 (en) Naphthalene derivatives their preparation and intermediates thereof
ZA967654B (en) Electrodes and methods of preparation thereof
HUP0001266A3 (en) Lipid complexes and liposomes of highly insoluble platinum complexes
ZA986437B (en) Derivatives of acyl-piperazinyl-pyrimidines their preparation and application as medicaments
EP0748327A4 (en) Structure of a novel lipid a and methods utilizing same
ZA984266B (en) Pharmaceutical composition and process of preparation
BR9504463A (en) Process for preparation of quetoprofen liposomes and pharmaceutical preparations
ZA988496B (en) Novel imidazolidine derivatives their preparation their use and pharmaceutical preparations comprising them
NZ300198A (en) Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines
AU7428691A (en) Long-acting liposome peptide pharmaceutical products and processes for the preparation thereof
IL123322A0 (en) Tetrahydroquinolines their preparation and pharmaceutical compositions containing them
PL332696A1 (en) Carriers containing a combination of enterolipoid and of a lipoid of complementary shape and their therapeutic applications
IL113811A0 (en) Preparation of 9-amino camptothecin
IL117078A0 (en) Substituted benzenesulfonylureas and -thioureas processes for their preparation their use for the production of pharmaceutical preparations and pharmaceutical preparations containing them
IL113135A0 (en) Liposomes and suspensions thereof comprising multilamellar liposomes
AU691677B2 (en) Tetrahydroisoquinoline derivative and medicinal preparation containing the same